RxDoctor Payments Data

Patricia Shepard

Primary Care · Carlsbad, NMNPI 1386108546

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Acella Pharmaceuticals, LLC at 30.6% of the total.

$305in general payments, 2019–2025

Across 19 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acella Pharmaceuticals, LLC$93
  • Lilly USA, LLC$84
  • AstraZeneca$46
  • Exact Sciences$34
  • Novo Nordisk$16
  • AbbVie$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$305 in reported general payments places this provider in the 55th percentile of 58 primary care providers in New Mexico.

See all primary care providers in New Mexico

Medicare billing

Part B allowed, 2024
$50,008
Medicare patients
139
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$22,658
JardianceEmpagliflozin12$21,342
TrulicityDulaglutide17$16,616
JanuviaSitagliptin Phosphate11$15,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,058
VascepaIcosapent Ethyl12$4,188
Levothyroxine Sodium142$1,730
Albuterol Sulfate HfaAlbuterol Sulfate64$1,544
Gabapentin67$1,230
Armour ThyroidThyroid,pork19$1,207
Rosuvastatin Calcium40$1,180
Lisinopril120$950
Metformin Hcl64$867
Atorvastatin Calcium80$683
Losartan Potassium58$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$22,65816 claims
Lilly USA, LLCTrulicity$84$16,61617 claims
AbbVieArmour Thyroid$16$1,20719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 58 primary care providers in New Mexico.

Other primary care in Carlsbad

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →